about
Combinatorial RNA-based gene therapy for the treatment of HIV/AIDSMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialDevelopment of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical PracticeOptimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance geneRole of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.Diabetes and HIV: current understanding and future perspectives.Raltegravir as antiretroviral therapy in HIV/AIDS.Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells.Role of Autophagy in HIV Pathogenesis and Drug Abuse.Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.Impact of Moringa oleifera lam. Leaf powder supplementation versus nutritional counseling on the body mass index and immune response of HIV patients on antiretroviral therapy: a single-blind randomized control trial.Prevalence of renal disease within an urban HIV-infected cohort in northern Italy.Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.Phylogenetic analysis of HIV-1 subtypes and drug resistance profile among treatment-naïve people in Kuwait.Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain.Safety and tolerability of tenofovir for preexposure prophylaxis among men who have sex with men.The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years.Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
P2860
Q26866145-82317D60-735B-4DAD-8B1F-725A3095C13BQ28540037-37626A82-EEED-48B7-A14D-147925307EBDQ29036869-E32FCAF3-7E79-4BF4-9F68-DD6A53AD19F4Q33586969-3650C471-7800-4CBF-B241-4AFC483980CBQ36309602-BB312C33-8980-4DDB-8439-B7CDF4FC66D6Q36888917-90267125-18F7-4D3A-B268-8BB3FF7FD775Q37406571-57ED4F8E-180D-455E-94A8-94447799A0BDQ38085218-86E60EF7-D3CB-4101-BA25-DF5FA2D4461EQ38168587-92043DB0-8D31-451A-822F-E6DD80F739BBQ38170576-0412E534-FF39-42DA-AF9A-08F6A3442496Q38911295-920F43E5-2678-4CA4-8792-B6DE1A331BD5Q38962319-FC49B036-571F-41CC-9B21-9DBD9FDA24BCQ39037792-6836D124-9126-411F-A92D-A29E85B031EEQ40075047-4706B636-F557-4A74-8C1C-0C8E655145E5Q40113698-C1DBF3A4-9C37-4392-9553-84DA3EF60981Q40435430-D35AF68B-F545-43F3-87D8-0FFC7DFA00BAQ40846333-12488275-F437-4951-B9C2-AB342236DB05Q41229580-0DD4CFF8-19B4-415B-B0D7-EBE0BD06455BQ42284456-BB377B5F-9BFC-4BA8-BE4F-1B7822E7682DQ42919941-AF088E8D-9AB2-48E5-B3DB-7A998C33D1F8Q52314047-8A881C6B-765B-4952-B4DD-9FD171E8FD7CQ52592228-BC0FD9DA-7997-4B9A-8963-C23E8B49DA70
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Renal toxicity associated with antiretroviral therapy.
@en
type
label
Renal toxicity associated with antiretroviral therapy.
@en
prefLabel
Renal toxicity associated with antiretroviral therapy.
@en
P2860
P356
P1433
P1476
Renal toxicity associated with antiretroviral therapy.
@en
P2093
Leonardo Calza
P2860
P304
P356
10.1310/HCT1304-189
P577
2012-07-01T00:00:00Z